Related Experiment Video
Updated: Oct 12, 2025
Creation and Transplantation of an Adipose-derived Stem Cell ASC Sheet in a Diabetic Wound-healing Model
Published on: August 4, 2017
Angiogenin Released from ABCB5+ Stromal Precursors Improves Healing of Diabetic Wounds by Promoting Angiogenesis
Karmveer Singh1, Pallab Maity1, Albert Kallon Koroma1
1Department of Dermatology and Allergic Diseases, Ulm University, Ulm, Germany.
Abstract:
Severe angiopathy is a major driver for diabetes-associated secondary complications. Knowledge on the underlying mechanisms essential for advanced therapies to attenuate these pathologies is limited. Injection of ABCB5+ stromal precursors at the edge of nonhealing diabetic wounds in a murine db/db model, closely mirroring human type 2 diabetes, profoundly accelerates wound closure. Strikingly, enhanced angiogenesis was substantially enforced by the release of the ribonuclease angiogenin from ABCB5+ stromal precursors. This compensates for the profoundly reduced angiogenin expression in nontreated murine chronic diabetic wounds. Silencing of angiogenin in ABCB5+ stromal precursors before injection significantly reduced angiogenesis and delayed wound closure in diabetic db/db mice, implying an unprecedented key role for angiogenin in tissue regeneration in diabetes. These data hold significant promise for further refining stromal precursors-based therapies of nonhealing diabetic foot ulcers and other pathologies with impaired angiogenesis.
Insights
Injecting ABCB5+ stromal precursors accelerates diabetic wound healing by releasing angiogenin. This discovery offers new hope for treating nonhealing diabetic foot ulcers and other conditions with poor blood vessel formation.
Area of Science:
- Regenerative Medicine
- Diabetology
- Vascular Biology
Background:
- Diabetic complications, including severe angiopathy, significantly impact patient health.
- Understanding the mechanisms behind diabetic pathologies is crucial for developing effective treatments.
- Nonhealing diabetic wounds represent a major clinical challenge, often linked to impaired angiogenesis.
Purpose of the Study:
- To investigate the therapeutic potential of ABCB5+ stromal precursors in accelerating diabetic wound closure.
- To elucidate the role of angiogenin in mediating the pro-angiogenic effects of stromal precursors in diabetic wounds.
- To explore the feasibility of stromal precursor-based therapies for nonhealing diabetic foot ulcers.
Main Methods:
- Utilized a murine db/db model, which closely mimics human type 2 diabetes and associated wound healing deficits.
- Administered ABCB5+ stromal precursors to the wound edges of diabetic mice.
- Investigated the expression and function of angiogenin in both treated and untreated diabetic wounds, including experiments with silenced angiogenin in precursors.
Main Results:
- Injection of ABCB5+ stromal precursors significantly accelerated wound closure in diabetic mice.
- Enhanced angiogenesis was observed, driven by the release of angiogenin from the administered precursors.
- Silencing angiogenin in the precursors abrogated the pro-healing and pro-angiogenic effects, confirming angiogenin's critical role.
- Diabetic wounds showed significantly reduced endogenous angiogenin expression compared to controls.
Conclusions:
- ABCB5+ stromal precursors promote diabetic wound healing through angiogenin-mediated angiogenesis.
- Angiogenin plays an unprecedented key role in tissue regeneration within the context of diabetes.
- These findings support the development of advanced stromal precursor-based therapies for diabetic foot ulcers and other conditions characterized by impaired angiogenesis.
Related Concept Videos
01:10Mechanism of Angiogenesis
01:24Regulation of Angiogenesis and Blood Supply